Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SGMT Stock Forecast 2026-2027
$6.19
Current Price
$201.70M
Market Cap
Buy 9
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to SGMT Price Targets
+465.4%
To High Target of $35.00
+336.2%
To Median Target of $27.00
+29.2%
To Low Target of $8.00
SGMT Price Momentum
+16.8%
1 Week Change
+19.3%
1 Month Change
+180.1%
1 Year Change
+4.6%
Year-to-Date Change
-45.7%
From 52W High of $11.41
+206.4%
From 52W Low of $2.02
📊 TOP ANALYST CALLS
Did SGMT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Sagimet Biosciences is one of their latest high-conviction picks.
Latest SGMT Stock Price Targets & Analyst Predictions
Based on our analysis of 14 Wall Street analysts, SGMT has a bullish consensus with a median price target of $27.00 (ranging from $8.00 to $35.00). The overall analyst rating is Strong Buy (9.4/10). Currently trading at $6.19, the median forecast implies a 336.2% upside. This outlook is supported by 9 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jonathan Wolleben at Citizens, projecting a 465.4% upside. Conversely, the most conservative target is provided by Eliana Merle at Barclays, suggesting a 29.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SGMT Analyst Ratings
9
Buy
1
Hold
0
Sell
SGMT Price Target Range
Low
$8.00
Average
$27.00
High
$35.00
Current: $6.19
Latest SGMT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SGMT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 11, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $29.00 |
| Feb 3, 2026 | Guggenheim | Seamus Fernandez | Buy | Initiates | $27.00 |
| Feb 3, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $29.00 |
| Jan 28, 2026 | Barclays | Eliana Merle | Equal-Weight | Initiates | $8.00 |
| Nov 14, 2025 | Citizens | Jonathan Wolleben | Market Outperform | Maintains | $35.00 |
| Oct 22, 2025 | Clear Street | Kaveri Pohlman | Buy | Initiates | $29.00 |
| Oct 2, 2025 | Canaccord Genuity | Edward Nash | Buy | Maintains | $28.00 |
| Aug 11, 2025 | Wedbush | Yun Zhong | Outperform | Initiates | $28.00 |
| Aug 7, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Assumes | $29.00 |
| Jul 24, 2025 | Canaccord Genuity | Edward Nash | Buy | Initiates | $28.00 |
| Jun 6, 2025 | Jones Trading | Debanjana Chatterjee | Buy | Maintains | $27.00 |
| Mar 13, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Mar 11, 2025 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Jan 27, 2025 | Jones Trading | Debanjana Chatterjee | Buy | Initiates | $42.00 |
| Dec 6, 2024 | Oppenheimer | Jay Olson | Outperform | Initiates | $30.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Nov 12, 2024 | UBS | Eliana Merle | Buy | Initiates | $12.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Oct 2, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $32.00 |
Sagimet Biosciences Inc. (SGMT) Competitors
The following stocks are similar to Sagimet Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Sagimet Biosciences Inc. (SGMT) Financial Data
Valuation Metrics
Market Cap
$201.70M
Enterprise Value
$84.75M
P/E Ratio
N/A
PEG Ratio
-3.2x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+56.1%
Current Ratio
22.8x
Debt/Equity
0.1x
ROE
-38.2%
ROA
-25.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Sagimet Biosciences Inc. (SGMT) Business Model
About Sagimet Biosciences Inc.
What They Do
Develops therapeutics for fibrotic diseases and cancer.
Business Model
The company leverages its proprietary platform to discover and develop small molecule drugs targeting critical metabolic pathways. It generates revenue through the advancement of its drug pipeline, which includes programs for treating nonalcoholic steatohepatitis (NASH) and specific cancers, addressing unmet medical needs.
Additional Information
Sagimet Biosciences emphasizes precision medicine and first-in-class therapeutics, setting it apart in the pharmaceutical industry. Its focus on innovative treatment options positions it as a significant player in drug discovery and development.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
16
CEO
Mr. David A. Happel
Country
United States
IPO Year
2023
Website
www.sagimet.comSagimet Biosciences Inc. (SGMT) Latest News & Analysis
Latest News
Quick Summary
Sagimet Biosciences (Nasdaq: SGMT) will present data from its Phase 2b FASCINATE 2 trial of denifanstat at the Fueling MASH Symposium on April 12-15, 2026, in Vancouver, Canada.
Why It Matters
The announcement of presentations at a key symposium highlights Sagimet Biosciences' progress in clinical trials, potentially boosting investor confidence in the company's future prospects and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Sagimet Biosciences completed a Phase 1 PK trial for denifanstat/resmetirom and plans a Phase 2 trial for F4 MASH patients in 2H 2026. They secured a global license for resmetirom API and reported positive Phase 3 results for denifanstat in acne.
Why It Matters
The successful clinical trials and licensing agreements indicate potential for future revenue and market expansion for Sagimet Biosciences, impacting its stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Sagimet Biosciences Inc. (SGMT) presented at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, highlighting key developments and insights into its business strategy.
Why It Matters
Sagimet Biosciences' presentation may signal advancements in its pipeline, influencing stock performance and investor confidence in its growth potential.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Sagimet Biosciences Inc. (Nasdaq: SGMT) will participate in three investor conferences, highlighting its focus on developing therapeutics for metabolic and fibrotic conditions.
Why It Matters
Sagimet Biosciences' participation in investor conferences indicates potential for increased visibility and interest in its clinical developments, which could impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Sagimet Biosciences Inc. (Nasdaq: SGMT) will participate in two investor conferences, focusing on its development of therapeutics for metabolic and fibrotic pathways.
Why It Matters
Sagimet Biosciences' participation in investor conferences signals potential growth and visibility, which may attract investor interest and impact stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Sagimet Biosciences (Nasdaq: SGMT) announced Ascletis Pharma's positive topline results from a Phase 3 trial of ASC40 for treating moderate to severe acne.
Why It Matters
Positive Phase 3 trial results for ASC40 may enhance market perception of Ascletis Pharma, potentially boosting Sagimet Biosciences' stock through increased interest in related biotech advancements.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SGMT Stock
What is Sagimet Biosciences Inc.'s (SGMT) stock forecast for 2026?
Based on our analysis of 14 Wall Street analysts, Sagimet Biosciences Inc. (SGMT) has a median price target of $27.00. The highest price target is $35.00 and the lowest is $8.00.
Is SGMT stock a good investment in 2026?
According to current analyst ratings, SGMT has 9 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.19. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SGMT stock?
Wall Street analysts predict SGMT stock could reach $27.00 in the next 12 months. This represents a 336.2% increase from the current price of $6.19. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Sagimet Biosciences Inc.'s business model?
The company leverages its proprietary platform to discover and develop small molecule drugs targeting critical metabolic pathways. It generates revenue through the advancement of its drug pipeline, which includes programs for treating nonalcoholic steatohepatitis (NASH) and specific cancers, addressing unmet medical needs.
What is the highest forecasted price for SGMT Sagimet Biosciences Inc.?
The highest price target for SGMT is $35.00 from Jonathan Wolleben at Citizens, which represents a 465.4% increase from the current price of $6.19.
What is the lowest forecasted price for SGMT Sagimet Biosciences Inc.?
The lowest price target for SGMT is $8.00 from Eliana Merle at Barclays, which represents a 29.2% increase from the current price of $6.19.
What is the overall SGMT consensus from analysts for Sagimet Biosciences Inc.?
The overall analyst consensus for SGMT is bullish. Out of 14 Wall Street analysts, 9 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $27.00.
How accurate are SGMT stock price projections?
Stock price projections, including those for Sagimet Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 17, 2026 11:42 AM UTC